PacBio, TychoBio Team Up to Build AI Models for Rare Disease Treatments

Pacific Biosciences and TychoBio have announced a collaboration aimed at accelerating drug discovery for rare diseases by combining long-read genomic sequencing with artificial intelligence modeling, the companies said in a joint statement.

At the core of the partnership is PacBio's Kinnex sequencing platform, which is designed to generate full-length RNA transcript data. That data will serve as training material for TychoBio's AI models, which are focused on identifying and developing RNA-based therapeutics for patients with rare conditions.

Read more Prophix Partners With PwC Belgium to Modernize Finance Functions →

RNA therapeutics represent a rapidly evolving class of medicines that work by targeting the genetic instructions cells use to produce proteins, offering potential treatment pathways for diseases that have historically had few or no options. Full-length transcript data is considered particularly valuable in this context because it captures complete genetic readouts rather than fragmented sequences, giving AI systems richer information from which to learn.

The collaboration reflects a broader industry trend of pairing next-generation sequencing infrastructure with machine learning pipelines to compress the early stages of pharmaceutical research. By feeding high-fidelity genomic data directly into computational drug discovery workflows, companies aim to reduce the time and cost associated with identifying viable therapeutic candidates.

Neither company disclosed financial terms of the agreement or a projected timeline for advancing candidates toward clinical development. Continue reading at GlobeNewswire - Industry News on Financial Services.